NDAORALTABLETPriority Review
Approved
May 2020
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
8
Data completeness
6/8 — Strong
Priority Review
QINLOCK (ripretinib) by Cipher Pharmaceuticals is stem cell factor (kit) receptor inhibitors [moa]. Approved for gastrointestinal stromal tumor. First approved in 2020.
Drug data last refreshed 20h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
QINLOCK (ripretinib) is an oral kinase inhibitor that targets the Stem Cell Factor (KIT) receptor, approved by the FDA on May 15, 2020. It is indicated for gastrointestinal stromal tumors (GIST), specifically for patients who have received prior treatment with other KIT inhibitors. The drug works by inhibiting KIT receptor signaling, a key driver of GIST oncogenesis. QINLOCK represents a fourth-line or later treatment option for advanced GIST, filling an important clinical gap for patients with imatinib-resistant disease.
$0.1BPart D
16.4 years to LOEMechanism of Action
Stem Cell Factor (KIT) Receptor Inhibitors
Pharmacologic Class:
Kinase Inhibitor
Indications (1)
Clinical Trials (8)
Ripretinib (QINLOCK®) According to Current SmPC
Started Oct 2024
10 enrolled
GIST - Gastrointestinal Stromal Tumor
A Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With Specific KIT Exon Mutations Who Were Previously Treated With Imatinib
Started Dec 2023
54 enrolled
GIST
Ripretinib in Combination With Binimetinib in Patients With Gastrointestinal Stromal Tumor (GIST)
Started Nov 2021
0Gastrointestinal Stromal Tumors
A Drug-Drug Interaction Study to Evaluate the Effect of Ripretinib on the Pharmacokinetics of a CYP2C8 Probe Substrate in Patients with Advanced GIST
Started Sep 2021
13 enrolled
GIST - Gastrointestinal Stromal Tumor
Ripretinib in Chinese Patients With Advanced GIST: a Real World Study
Started May 2021
308 enrolled
Gastrointestinal Stromal Tumors
Worked on QINLOCK at Cipher Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.